Press release
Histone Deacetylase (HDAC) Inhibitors Market Drivers, Key Players, Share, Market Size And Forecast To 2033
Histone Deacetylase (HDAC) Inhibitors Market Drivers
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp
According to The Business Research Company's, The histone deacetylase (HDAC) inhibitors market size has grown strongly in recent years. It will grow from $1.15 billion in 2023 to $1.23 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to a rise in funding for epigenetic research, rising prevalence of drug-resistant cancers, rise in healthcare expenditure, increasing utilization of HDAC inhibitors in veterinary medicine, and increasing investment in bioinformatics.
The histone deacetylase (HDAC) inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.65 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to the rising incidence of neurodegenerative disorders, growing awareness about cancer, rising investment in drug development, growing number of clinical trials, and increasing adoption of personalized medicine. Major trends in the forecast period include technological advancements, personalized medicine, cancer immunotherapy synergies, integration of digital health solutions, and bioinformatics.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/histone-deacetylase-hdac-inhibitors-global-market-report
Market Drivers and Trends:
The rising incidence of neurodegenerative disorders is expected to propel the growth of the histone deacetylase (HDAC) inhibitors market going forward. Neurodegenerative disorders, characterized by the progressive degeneration and death of neurons in the brain and spinal cord, lead to cognitive and motor dysfunction and include diseases such as Alzheimer's, marked by memory loss and cognitive decline due to amyloid plaques and tau tangles. The rising incidence of neurodegenerative disorders can be attributed to several factors, such as age, longevity, genetics, and environmental factors. Histone deacetylase (HDAC) inhibitors are being explored as potential treatments for neurodegenerative disorders due to their ability to modulate gene expression and provide neuroprotective effects. For instance, in March 2021, according to the National Institutes of Health (NIH), a US-based government agency, currently, 6.2 million older Americans are living with Alzheimer's dementia, and this number is projected to increase to 13.8 million by 2060. Therefore, the rising incidence of neurodegenerative disorders is driving the growth of the histone deacetylase (HDAC) inhibitors market.
Major companies operating in the histone deacetylase (HDAC) inhibitors market are focused on developing innovative solutions, such as HDAC inhibitors for cancer treatment, to enhance efficacy and reduce side effects. Histone deacetylase (HDAC) inhibitors are a class of pharmaceutical compounds used in cancer treatment. They function by inhibiting the activity of HDAC enzymes, which generally remove acetyl groups from histone proteins. This inhibition leads to increased acetylation of histones, altering chromatin structure and influencing gene expression. For instance, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based company that develops first-in-class therapies for cancer, was awarded New HDAC Inhibitor Patents for Cancer Treatment by the U.S. Patent and Trademark Office. These innovative inhibitors are tailored to target specific HDAC enzymes implicated in cancer progression, aiming to disrupt aberrant gene expression patterns that contribute to tumor growth and metastasis. The patented compounds demonstrate enhanced potency and selectivity, minimizing off-target effects and improving safety profiles for patients undergoing treatment.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Major Key Players of the Market:
Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.
Histone Deacetylase (HDAC) Inhibitors Market 2024 Key Insights:
• The histone deacetylase (HDAC) inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.65 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%.
• Rising Neurodegenerative Disorders Drive Growth In HDAC Inhibitors Market
• Shuttle Pharmaceuticals Advances Cancer Treatment With New HDAC Inhibitor Patents
• North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/customise?id=18386&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (https://www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Histone Deacetylase (HDAC) Inhibitors Market Drivers, Key Players, Share, Market Size And Forecast To 2033 here
News-ID: 3730994 • Views: …
More Releases from The Business research company
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for HDAC
Rising Neurodegenerative Disorders Drive Growth In HDAC Inhibitors Market: Pivot …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Histone Deacetylase (HDAC) Inhibitors Market Size Growth Forecast: What to Expect by 2025?
The market for histone deacetylase (HDAC) inhibitors has seen substantial growth in the last few years. The market is predicted to expand from a size of $1.23 billion in 2024 to $1.33 billion in 2025, with…
HDAC Inhibitors Market Projected to Grow Significantly Through 2034 | DelveInsig …
The HDAC Inhibitors companies in the market include - Merck & Co., Bristol Myers Squibb, Celgene Corporation, Spectrum Pharmaceuticals, and Syndax Pharmaceuticals, among others.
The HDAC inhibitor market has shown significant growth in recent years, driven by the increasing prevalence of several key indications commonly treated with HDAC inhibitors, growing research in epigenetics, and expanding applications beyond oncology. According to DelveInsight's comprehensive analysis, key pharmaceutical companies, including Merck & Co., Bristol…
Key Trend Reshaping the Histone Deacetylase (HDAC) Inhibitors Market in 2025: Sh …
Which drivers are expected to have the greatest impact on the over the histone deacetylase (hdac) inhibitors market's growth?
The increasing incidence of neurodegenerative diseases is expected to drive the growth of the histone deacetylase (HDAC) inhibitors market. Neurodegenerative disorders, such as Alzheimer's disease, involve the progressive degeneration of neurons, leading to cognitive and motor dysfunction. The rising prevalence of these disorders is due to aging, genetics, and environmental factors. HDAC…
HDAC Inhibitor Treatment Drugs, Clinical Trials, Pipeline Insights, and Companie …
DelveInsight's, "HDAC Inhibitor Pipeline Insight 2024" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HDAC Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our comprehensive HDAC Inhibitor Pipeline Report to stay informed about…
Histone Deacetylase (HDAC) Inhibitors Market 2022 | Detailed Report
The Histone Deacetylase (HDAC) Inhibitors research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market's key players. Furthermore, the report offers insightful market data and information about the…
HDAC Inhibitors Market - Increasing R&D activities for cancer is expected to boo …
Overview
HDAC inhibitors are a kind of anti-cancer drug that works by causing cell cycle arrest, apoptosis, and death in cancer cells through non-epigenetic or epigenetic control. HDAC inhibitors (HDACi) are potential medicines that have already demonstrated promise in oncological applications such as cancer detection, treatment, and prognostic. Vorinostat (Merck & Co. Inc.) is a new medication that is used to treat epidermal T cell lymphoma as it progresses, relapses, or…
